HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Heart Failure With Preserved Ejection Fraction
  • Age: Between 55 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects who are at least 55 years old
    2. Subjects must have at least one of the following:
      • Prior MI
      • Prior ischemic stroke
      • Peripheral artery disease as evident by prior lower extremity artery revascularization or aortic aneurysm repair

You may not be eligible for this study if the following are true:

    1. Subjects with acute coronary syndrome or stroke less than 4 weeks before
    2. Subjects with Coronary revascularization procedure planned within the next 6 months
    3. Subjects with Known chronic liver disease
    4. Subjects who have current or planned renal dialysis or transplantation
    5. Subjects with previous exposure to inclisiran or participation in a randomized trial of inclisiran
    6. Previous, current or planned treatment with a monoclonal antibody targeting PCSK9, or with a drug known to be contra-indicated with inclisiran
    7. Known to be poorly compliant with clinic visits or prescribed medication
    8. Subjects who are pregnant or lactating.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.